Gabapentin
- Generic Name
- Gabapentin
- Brand Names
- Gralise, Neurontin
- Drug Type
- Small Molecule
- Chemical Formula
- C9H17NO2
- CAS Number
- 60142-96-3
- Unique Ingredient Identifier
- 6CW7F3G59X
- Background
Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures - today it is also widely used to treat neuropathic pain. Gabapentin has some stark advantages ...
- Indication
In the United States, gabapentin is officially indicated for the treatment of postherpetic neuralgia in adults and for the adjunctive treatment of partial-onset seizures, with or without secondary generalization, in patients 3 years of age and older. In Europe, gabapentin is indicated for adjunctive therapy in the treatment of partial-onset seizures, with or...
- Associated Conditions
- Partial-Onset Seizures, Peripheral Neuropathic Pain, Postherpetic Neuralgia
- Associated Therapies
- -
Comparing the Treatment of Alcohol Withdrawal Syndrome Using Gabapentin Versus Lorazepam
- Conditions
- First Posted Date
- 2005-09-29
- Last Posted Date
- 2005-09-29
- Target Recruit Count
- 160
- Registration Number
- NCT00229125
- Locations
- 🇺🇸
Medical University of South Carolina - Center for Drug and Alcohol Programs, Charleston, South Carolina, United States
Clinical Trial of Gabapentin to Decrease Postoperative Delirium and Pain
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 750
- Registration Number
- NCT00221338
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Dextromethorphan, Gabapentin, and Oxycodone to Treat Opioid-Induced Hyperalgesia
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 60
- Registration Number
- NCT00218374
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
Optimal Multimodal Analgesia in Laparoscopic Cholecystectomy
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2005-09-21
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00209885
- Locations
- 🇩🇰
Dept of Anaesthesia, Hvidovre Hospital, Copenhagen, Hvidovre, Denmark
Optimal Multimodal Analgesia in Abdominal Hysterectomy
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2007-11-07
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00209872
- Locations
- 🇩🇰
Dept. of Anaesthesia, Hvidovre Hospital, Copenhagen, Hvidovre, Denmark
Effects of Gabapentin in the Treatment of Neuropathic Pain on Driving Performance and Cognition
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-09-16
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 24
- Registration Number
- NCT00189072
- Locations
- 🇳🇱
University of Utrecht, Utrecht, Netherlands
Influence of Intestinal Transporter Genetic Variants on the Bioavailability of Gabapentin
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2012-08-09
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 30
- Registration Number
- NCT00187707
- Locations
- 🇺🇸
San Francisco General Hospital, San Francisco, California, United States
Gabapentin in Phantom and Stump Pain
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Danish Pain Research Center
- Registration Number
- NCT00169013
- Locations
- 🇩🇰
Danish Pain Research Center, Aarhus University Hospital, Aarhus, Denmark
A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2021-02-02
- Target Recruit Count
- 256
- Registration Number
- NCT00163046
- Locations
- 🇺🇸
Pfizer Investigational Site, Overland Park, Kansas, United States
Study of Efficacy of Gabapentin in Therapy of Bronchial Asthma
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2009-02-19
- Lead Sponsor
- Centre of Chinese Medicine, Georgia
- Target Recruit Count
- 68
- Registration Number
- NCT00153283
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.